[Articles] Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus–Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study

Data ReadoutpositiverVSV-ZEBOVPositive

AI Analysis

Summary

A longitudinal cohort study published in The Lancet provides the first human data describing Bundibugyo virus glycoprotein seroreactivity following rVSV-ZEBOV vaccination in outbreak-affected populations in the Democratic Republic of the Congo, revealing differing patterns between geographic regions.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Longitudinal cohort study provides first human data describing Bundibugyo virus glycoprotein seroreactivity following licensed Ebola virus disease vaccination in outbreak-affected populations

Importance:5/10

Sentiment:

0.60

EbolavaccinationseroreactivityDemocratic Republic of the CongoBundibugyo viruslongitudinal study

Related Companies

$MRK

Read the original article

Published by The Lancet on August 25, 2026 10:30 PM

Read Original